MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/1759720x221074457

Медицинская библиотека · Therapeutic advances in musculoskeletal disease · 2022

The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.

Liang Minrui, Matteson Eric L, Abril Andy, Distler Jörg H W

СтатьяОбзорПеревод в очереди

Аннотация

The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved patient outcomes. However, exceptionally high medical needs still remain for effective therapies for the patients with ILD in RA. Better understanding of the shared and distinct pathophysiology of fibrotic diseases led to the development of novel antifibrotic agents such as nintedanib and pirfenidone. The further stratification analysis of the phase III INBUILD trial demonstrated beneficial effects of nintedanib in RA-ILD with a progressive phenotype by reducing the rate of decline in forced vital capacity (FVC) over 52 weeks by 60%. Pirfenidone is another antifibrotic agent currently under phase II clinical study (TRAIL1) aiming to evaluate its effects for RA-ILD. This review provides an overview of state-of-the-art pathogenesis and the current therapeutic options for RA-ILD, with a focus on antifibrotic strategies.

Для цитирования: Liang Minrui, Matteson Eric L, Abril Andy, Distler Jörg H W. The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.. Therapeutic advances in musculoskeletal disease. 2022. DOI: 10.1177/1759720x221074457.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.